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Ciliary neurotrophic factor (CNTF) has been shown to prevent behavioral deficits and striatal degeneration in neurotoxic models of
Huntington’s disease (HD), but its effect in a genetic model has not been evaluated. Lentiviral vectors expressing the human CNTF or LacZ
reporter gene were therefore injected in the striatum of wild-type (WT) and transgenic mice expressing full-length huntingtin with 72 CAG
repeats (YAC72). Behavioral analysis showed increased locomotor activity in 5- to 6-month-old YAC72-LacZ mice compared to WT-LacZ
animals. Interestingly, CNTF expression reduced the activity levels of YAC72 mice compared to control animals. In both WT and YAC72
mice, CNTF expression was demonstrated in striatal punches, up to a year after lentiviral injection. Stereological analysis revealed that the
number of LacZ and DARPP-32-positive neurons were decreased in YAC72-LacZ mice compared to WT-LacZ animals. Assessment of the
benefit of CNTF expression in the YAC72 mice was, however, complicated by a down-regulation of DARPP-32 and to a lesser extent of
NeuN in all mice treated with CNTF. The expression of the neuronal marker NADPH-d was unaffected by CNTF, but expression of the
astrocytic marker glial fibrillary acidic protein (GFAP) was increased. Finally, a reduction of the number of striatal dark cells was observed in
YAC mice treated with CNTF compared to LacZ. These data indicate that sustained striatal expression of CNTF can be achieved with
lentiviruses. Further studies are, however, needed to investigate the intracellular signaling pathways mediating the long-term effects of CNTF
expression on dopamine signaling, glial cell activation and how these changes may affect HD pathology.
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Introduction envisaged. Over the last few years, neuroprotective strate-Huntington’s disease (HD) is a fatal dominant disorder
characterized by a selective neuronal loss in the striatum and
to a lesser extent in the cortex (Vonsattel and Difiglia, 1998).
The disorder is caused by an expansion of a CAG repeat
tract in the HD gene (The Huntington’s Disease Collabora-
tive Research Group, 1993) which can be used to geneti-
cally identify presymptomatic individuals who are at-risk
for developing the disease (Andrew et al., 1993). Initiation
of therapeutic interventions before the onset of clinical
symptoms and neuronal degeneration can therefore be0014-4886/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.expneurol.2003.09.002
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E-mail address: nicole.deglon@epfl.ch (N. De´glon).gies based on the use of neurotrophic factors have been
developed, and significant rescue of striatal neurons associ-
ated with behavioral improvement was observed in drug-
induced models of HD (Anderson et al., 1996; Araujo and
Hilt, 1998; Bemelmans et al., 1999; Emerich et al., 1996;
Frim et al., 1993; Mittoux et al., 2000; Perez-Navarro et al.,
1999, 2000; Volpe et al., 1998).
Ciliary neurotrophic factor (CNTF) (Ip and Yancopoulos,
1996), a member of the cytokine family, has been shown to
prevent behavioral deficits and striatal degeneration in
quinolinic acid-lesioned rats and primates (Anderson et
al., 1996; de Almeida et al., 2001; Emerich et al., 1996,
1997a,b). Recently, we have further investigated whether
CNTF could reduce neuronal dysfunction and neurodegen-
eration in monkeys chronically treated with 3-nitropropionic
acid (3-NP) (Mittoux et al., 2000). This study demonstrated
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the time of appearance of striatal dysfunction and motor/
cognitive symptoms, not only prevents neuronal degenera-
tion, but also alleviates functional deficits. Moreover, Sau-
dou et al. (1998) have demonstrated that CNTF rescues
primary rat striatal cultures from cell death caused by the
expression of a mutant htt fragment. This in vitro study
suggests that CNTF might alter the degeneration of
GABAergic neurons in a genetic model of the disease.
In the present study, we have assessed the effect of long-
term CNTF delivery in wild-type mice and HD YAC
transgenic mice expressing full-length htt with 72 CAG
repeats (Hodgson et al., 1999). These animals show elec-
trophysiological abnormalities at 6 months, a mild hyper-
kinetic movement disorder with a significantly increased
activity between 5 and 9 months. By 12 months of age,
these mice display an increase in the number of striatal dark
cells as measured by toluidine blue staining (Hodgson et al.,
1999). Lentiviral vectors were used to achieve local and
long-term delivery of CNTF in the brain while avoiding
side effects associated with systemic administration (Abicht
and Lochmuller, 1999). Lentiviruses expressing LacZ or
human CNTF were bilaterally injected into the corpus
striata of 4-month-old YAC72 mice and wild-type litter-
mates. Behavioral analyses were performed during the
entire experiment to monitor the progression of the disease.
Finally, at 13 months of age, the animals were sacrificed
and their brains processed to assess the effects of long-term
CNTF expression.Materials and methods
Lentiviral vector production
The cDNA coding for a nuclear-localized h-galactosidase
(LacZ) and the human CNTF (Aebischer et al., 1996) were
cloned in the SIN-W-PGK transfer vector (de Almeida et al.,
2001; De´glon et al., 2000). The packaging construct and the
vesicular stomatitis virus G protein (VSV-G) envelope used
in this study were the pCMVDR-8.92, pRSV-Rev and
pMD.G plasmids (Dull et al., 1998; Hottinger et al., 2000;
Naldini et al., 1996). The viral particles were produced by
transient transfection of 293 T cells as previously described
(Hottinger et al., 2000). LacZ- and CNTF-expressing viruses
were resuspended in phosphate-buffered saline (PBS) with
1% bovine serum albumin and matched for particle content
of 100,000 ng p24 antigen/ml as measurement by ELISA
(Perkin Elmer Life Sciences, MA, USA).
In vivo experiments
YAC72 mice and littermate wild type (mouse line FVB-
TgN (353G6-72) 2511, YAC72) and wild-type FVB/N (Iffa-
Credo, France) mice (Hodgson et al., 1999) were used in
these studies. The animals were housed in a controlledtemperature room that was maintained on a 12 h light/dark
cycle. Food and water were available ad libitum. The animals
injected with lentiviral vectors were maintained in ventilated
cabinets in biosafety level 2 laboratories. The experiments
were carried out in accordance with the European Commu-
nity Council directive (86/609/EEC) for care and use of
laboratory animals.
Injection of the lentiviruses
The concentrated viral stocks were thawed and re-sus-
pended by repeated pipetting. CNTF or LacZ-expressing
lentiviral vectors were stereotaxically injected in the left (1
Al) and right (1 Al) striatum of 4-month-old pentobarbital
anesthetized (75 mg/kg, i.p.) FVB/N and YAC72 mice using
a Hamilton syringe with a 33-gauge blunt tip needle (Ham-
ilton, Reno, NV, USA). The stereotaxic coordinates for the
injection were: 0.4 mm rostral to bregma; 1.8 mm lateral to
midline (LM); 3.5 mm ventral from the dural surface. The
suspension was injected at 0.2 Al/min by means of an
automatic injector (Stoelting Co., IL, USA) and the needle
was left in place for 5 min. The skin was closed using a 6-0
Vicryl suture (Ethicon, Johnson and Johnson, Brussels).
Behavioral analysis
Mice were placed in a monitoring box (10 10 30 cm)
(Digiscan Animal Activity Monitor, AccuScan Instruments,
OH, USA) and their activity recorded for 2 h. Infrared beam
breaks were converted into total distance traveled. The
activity was tested every other week at a fixed time
corresponding to the dark phase period for the animals
(inverted light cycle). The test was performed during the
entire experimental period.
CNTF measurements
The animals were sacrificed, perfused in ice-cold PBS
containing 0.02% ascorbic acid (Sigma, MO, USA) and
5000 U of heparin (Liquemin, Roche Pharma, Reinach,
Switzerland). The in vivo synthesis of CNTF was deter-
mined from 2-mm-long striatal punches taken around the
injection sites and from corresponding non-injected hemi-
spheres. The samples were rapidly frozen on dry ice and
kept at  80jC until processing. The samples were soni-
cated in 500 Al PBS, containing a cocktail of protease
inhibitors (pronase, thermolysin, chymotrypsin, trypsin,
papain; Roche Pharma, Reinach, Switzerland). Quantitative
analysis of the production of CNTF was performed by an
ELISA assay according to the supplier’s manual (R&D
system, Abington, UK).
Histological processing
The mice were sacrificed by a sodium pentobarbital
overdose and then transcardially perfused with a 4% para-
Fig. 2. Sustained lentiviral-mediated expression of CNTF in the striatum of
mice. Striatal punches from wild-type and YAC72 transgenic mice were
taken 2–54 weeks post-injection of CNTF- or LacZ-expressing lentiviral
vectors and processed for ELISA assay. Values below the detection level
(20 pg) were measured on non-injected hemispheres or LacZ-infected
striata (ctrl). Values are expressed as mean F SEM.
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removed, weighed and one hemisphere was post-fixed in
4% paraformaldehyde for approximately 24 h and cryopro-
tected in 25% sucrose/0.1 M PBS for 48 h. These samples
were frozen in dry ice and coronal sections were cut on a
sliding microtome cryostat (Cryocut 1800, Leica Micro-
systems, Nußloch, Germany) at a temperature of  20jC
and a thickness of 20 Am. Slices throughout the entire
striatum were collected and stored in 48-well trays (Costar,
Cambridge, MA, USA) as free-floating sections in PBS
containing 0.12 AM sodium azide. The trays were stored at
4jC until immunohistochemical processing.
The second brain hemisphere was post-fixed in 0.15%
glutaraldehyde in 0.1 M PBS (pH 7.2). Fifty-micrometer
sections were cut with a Leica Ultracut ultramicrotome and
cresyl violet stained to assess the appearance of dark cells.
Sections were put for 2 min in sodium acetate solution
containing 0.5% cresyl violet (Sigma) and than rinsed in the
acetate solution. The sections were dehydrated in ethanol,
passed in toluol and coverslipped with Merckoglas.
Histochemical analysis
Enzymatic staining for nicotinamide adenine dinucleotide
phosphate diaphorase (NADPH-d) was performed as previ-
ously described (Ellison et al., 1987). For immunohistochem-
ical stainings, endogenous peroxidase activity was quenched
with 0.1% diphenylhydrazine/PBS (37jC for 30 min) and
washed 3 times in PBS. Free-floating sections were incubated
overnight in 5% normal goat serum (NGS, Dako Diagnostics,
Untermu¨li, Switzerland)/0.1 M PBS at 4jC, followed by an
overnight reaction in a PBS/1% NGS solution, with the
respective antibodies: DARPP-32 (1:5000, Chemicon, CA,
USA), LacZ (1:500, 5 Prime 3 Prime Inc., USA), glial
fibrillary acidic protein (GFAP, 1:300, Clontech, CA, USA)Fig. 1. Schematic representation of the four plasmids used for the production of l
(Packaging construct), pRSV-Rev (Rev protein) and SIN-W-PGK (transfer vec
producing the matrix, capsid and nucleocapsid. LTR: long-terminal repeat. PGK
promoter. RRE: Rev-responsive element. SA: splice acceptor. SD: splice donor. SIN
coding for the reverse transcriptase and integrase. PolyA+: polyadenylation signa
glycoprotein. WPRE: post-transcriptional regulatory element from the woodchukand neuronal nuclei (NeuN, 1:400, Chemicon). After three
washes, the sections were incubated with the corresponding
biotinylated secondary antibodies (1:200, Vector Laborato-
ries, CA, USA) for 2 h at room temperature. Bound anti-
bodies were visualized with the ABC system (Vectastain
ABC Kit, Vector Laboratories) and 3,3V-diaminobenzidin as
chromogen (DAB Metal Concentrate, Pierce, IL, USA). The
sections were dehydrated in ethanol, passed in toluol and
coverslipped with Merckoglas. Secondary antibodies cou-
pled to fluorescent chromophores (Jackson ImmunoResearchentiviral vectors in 293 T cells. pMD.G (VSV-G envelope), pCMVDR-8.92
tor). CMV: cytomegalovirus promoter. GAG: structural precursor protein
: mouse phosphoglycerate kinase 1 promoter. RSV: Rous sarcoma virus
: self-inactivating (deletion of the U3 region of the 3VLTR). POL: sequence
l. PRO: protease. c: packaging signal. VSV.G: vesicular stomatitis virus G
hepatitis virus.
Fig. 3. Decreased hyperactivity in CNTF-treated YAC72 mice. Values
represent the mean of total distance in meters traveled in the activity box
during 2 h. The general activity of WT/LacZ and WT/CNTF mice were
similar and have been plotted together in the graph. LacZ-injected
transgenic mice (n = 6) displayed an increased activity starting at 5 months
of age, whereas YAC/CNTF mice (n = 7) displayed a normal activity.
Significant differences between the YAC/LacZ and the YAC/CNTF groups
were found at 5 and 8 months (* P = 0.04, ** P = 0.03). Values are
expressed as mean F SEM.
Fig. 4. Loss of LacZ-positive cells in the striatum of YAC72 mice at 9 months pos
wild-type and YAC72 mice. (B) Histogram showing the number of LacZ-infected
meanF SEM.
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goat anti-rabbit, 1:200). The sections were mounted on glass
slides with Fluorsave Reagent (Calbiochem-Novabiochem
Corporation, CA, USA).
Quantification of NADPH-d and LacZ-positive cells
Counts were performed on 9 NADPH-d stained sections
per animal (240 Am apart) and 18 LacZ-stained sections per
animal (120 Am apart). The number of cells was extrapo-
lated with the Abercrombie’s equation with the following
parameters: section thickness, 20 Am; nuclear diameter, 5
Am; section selection, 1/8 for LacZ and 1/16 for NADPH-d.
Stereological analysis
The quantification of the DARPP-32 and NeuN cells was
performed on 18 sections (120 Am apart) per animal with an
Olympus microscope and analyzed with the stereological
software C.A.S.T. Grid (The International Stereology Center
Olympus Albertslund, Denmark) using the optical dissector
method. Briefly, the striatum area (ROI) was defined at low
magnification (1.25 ) and striatum volume was integrated
using the method of Cavalieri. Neuronal count was per-
formed at a magnification of 100 on grid of 500 Am  300t-injection. (A) Photomicrograph of LacZ-infected cells in the striatum of a
cells in wild-type (n = 2) and YAC72 (n = 6) mice. Values are expressed as
D. Zala et al. / Experimental Neurology 185 (2004) 26–3530Am and the optical dissector was set at 10 Am. An average of
20 grids was used per section analyzed.
Data analyses
Data are expressed as meanF SEM and evaluated for
analysis of variance (ANOVA) followed by a Scheffe’s
PLSD post hoc test (JMP 3.0, SAS Institute Inc., USA).
The significance level was set at P < 0.05.Results
Stable and long-term transgene expression in the striatum
Fig. 1 shows the lentiviral vectors used for the assess-
ment of long-term in vivo expression of CNTF in wild-typeFig. 5. Significant reduction of cresyl violet-stained dark cells in YAC72-CNTF
injected with a LacZ- or CNTF-expressing lentivirus. Arrows show some hyperc
degenerating cells in the striatum of YAC72-CNTF (n = 7) and YAC72-LacZ (nand YAC72 mice. Striatal punches, collected up to a year
post-lentiviral injection, were processed for ELISA. Aver-
age values of approximately 500 pg CNTF/punch were
measured, whereas no CNTF was detected in control
animals or in animals injected with LacZ lentiviral vectors
(Fig. 2). CNTF expression was sustained and no significant
differences were observed over time, or between wild-type
and YAC72 mice (Fig. 2). These results further demonstrate
that lentiviral vectors lead to long-term and sustained
transgene expression in the CNS (De´glon and Aebischer,
2002).
Interestingly, the local and continuous delivery of CNTF
in the striatum of these mice was not associated with a loss
in body weight (26F 1 g WT-LacZ vs. 26F 4 g WT-CNTF
at 13 months), a side effect previously observed with sys-
temic administration of this neurotrophic factor (Penn et al.,
1997).mice. (A) Photomicrographs of dark cells in the striatum of YAC72 mice
hromatic and shrunken cells. (B) Histogram showing the total number of
= 6) (* P < 0.001). Values are expressed as meanF SEM.
Fig. 6. Stereological counts of DARPP-32-positive neurons. (A) DARPP-
32-stained striatal sections from WT-LacZ, WT-CNTF, YAC72-LacZ and
YAC72-CNTF. (B) Quantification of the total number of DARPP-32-
positive cells in the striatum of WT-LacZ (n = 3), WT-CNTF (n = 3),
YAC72-LacZ (n = 6) and YAC72-CNTF (n = 7) mice. Values are expressed
as meanF SEM.
Fig. 7. Analysis of NeuN-stained striatal sections. (A) NeuN-stained striatal
sections from WT-LacZ, WT-CNTF, YAC72-LacZ and YAC72-CNTF
mice. (B) Evaluation of the astrocytic response in WT and YAC72 mice.
Photomicrographs showing GFAP-stained striatal sections in WT-LacZ,
WT-CNTF, YAC72-LacZ and YAC72-CNTF injected animals. The
administration of CNTF for 9 months leads to a significant increase in
GFAP immunoreactivity. In YAC72-lacZ mice, the staining did not differ
from WT-LacZ animals.
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mice
The appearance of behavioral abnormalities, in particular
hyperactivity, was assessed by measuring locomotor activ-
ity with the open field test (Fig. 3). A progressive sponta-
neous hyperactivity, starting at 5 months of age, was
observed in the YAC72-LacZ mice (Fig. 3). Although a
large inter- and intra-individual variability was observed,
the total distance traveled was higher in YAC72-LacZ mice
than in wild-type animals. At 7 and 8 months, a significant
hyperactivity was recorded in the YAC72-LacZ mice com-
pared to the WT group (Fig. 3). Importantly, CNTF-treated
mice displayed lower spontaneous activities compared to
YAC72-LacZ mice and statistically significant differences
were observed at 5 (P = 0.04) and 8 months (P = 0.03)
(Fig. 3). Performances in other behavioral tests such as
foot-clasping and rotarod did not differ significantly be-
tween groups (data not shown).Brain weight and LacZ expression
Mouse brains were weighed to assess the global brain
weight loss. At 13 months of age, no significant differ-
ences were observed between wild-type and YAC72 mice
(WT-LacZ (n = 3): 0.610F 0.058 g, WT-CNTF (n = 3):
0.581F 0.038 g, YAC72-LacZ (n = 6): 0.576F 0.006 g,
YAC72-CNTF (n = 6): 0.599F 0.013 g).
In wild-type mice, 35,629 F 6662 LacZ-infected cells
covering a large area of the striatum were detected 9 months
post-injection (Fig. 4A). These results correspond to the
typical infected area observed 2 weeks post-infection (data
not shown). Interestingly, a smaller number of LacZ-posi-
tive cells (12,709F 464) was observed in YAC72-LacZ
injected animals probably due to the loss of infected cells
(Fig. 4B). Large nuclear structures with intense LacZ stain-
ing were observed in the striatum of YAC72-LacZ mice but
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differences in the observed pattern of LacZ expression may
reflect the ongoing neurodegenerative process occurring in
the YAC72 mice.
Dark cells
Cresyl violet-stained sections were used to reveal the
presence of striatal dark cells and assess the effect of CNTF
on the incidence of these cells. Dark hyperchromatic neu-
rons were visible in YAC72-LacZ mice (Fig. 5A), whereas
no sign of these cells was found in WT-LacZ and WT-CNTF
animals. The intra-striatal administration of CNTF signifi-
cantly reduced the number of dark cells: in YAC72-CNTF
mice (60F 16) compared to YAC72-LacZ mice (129F 12;
P < 0.001) (Figs. 5A and 5B). This effect was not limited to
the injection site but was observed throughout the striatum
(data not shown).
DARPP-32 and NeuN immunoreactivity
To further assess the effect of CNTF, stereological counts
of DARPP-32-stained sections were performed. This marker
of the striatal GABAergic spiny neurons (Ouimet et al.,
1998) is decreased in several mouse models of HD (Bibb et
al., 2000; Luthi-Carter et al., 2000; van Dellen et al., 2000).
Interestingly, the long-term expression of CNTF in WT
mice led to a decrease in DARPP-32 labeling as shown in
Fig. 6A. The neuritic staining and the number of DARPP-
32-positive neurons were reduced (1.10 106F 0.15) com-
pared with WT-LacZ animals (1.44 106F 0.15; P = 0.13)
(Fig. 6B). Unfortunately, this result precludes drawing any
conclusions from the YAC72 mice, on any potential pro-
tective effect of CNTF on medium spiny neurons (YAC72-
LacZ: 1.20 106F 0.07; YAC72-CNTF: 1.15 106F
0.11). To further investigate the pathology of 13-month-
old YAC72 mice and the effect of CNTF administration,
striatal sections were stained with the neuronal marker
NeuN. No significant change in the staining and number
of NeuN-positive cells was observed between WT-LacZ
(1.52 106F 0.06) and YAC72-LacZ mice (1.42 106F
0.10; P = 0.2) whereas a reduction in the number of NeuN-
positive neurons was observed in the CNTF-treated mice
(WT-CNTF: 1 .35  106 F 0 .12 ; YAC72-CNTF:
1.04 106F 0.07; P = 0.01) (Fig. 7A). Finally, immuno-
histochemical analysis of NADPH-d neurons, which are
spared in HD patients, failed to reveal any alterations in the
brain of WT and YAC72 mice treated or not with CNTF
(data not shown).
GFAP staining
Previous in vitro and in vivo studies have shown that
CNTF induces astrocyte differentiation (Kahn et al., 1995;
Mayer et al., 1994; Winter et al., 1995). We have therefore
performed a GFAP immunostaining to reveal the presence ofactivated astrocytes (Fig. 7B). Both WT-CNTF- and YAC72-
CNTF-injected animals showed a substantial GFAP immu-
noreactivity (Fig. 7), whereas only few GFAP-positive astro-
cytes were visible in WT-LacZ- and YAC72-LacZ-injected
mice (Fig. 7).Discussion
In the present study, we assessed the effect of local and
long-term lentiviral-mediated CNTF expression in the stria-
tum of wild-type and HD transgenic mice. Lentiviral vectors
led to robust transgene expression up to 9 months post-
injection in the striatum of mice (De´glon and Aebischer,
2002) and lentiviral-mediated CNTF delivery was shown to
protect striatal neurons in a drug-induced rat model of HD
(de Almeida et al., 2001). Lentiviruses expressing the LacZ
reporter gene or human CNTF gene were therefore injected
bilaterally in 4-month-old wild-type and YAC72 mice. Nine
months post-injection, approximately 35,000 LacZ-infected
cells were counted in wild-type mice, whereas a reduction in
the number of h-galactosidase-positive cells was observed
in five out of the six HD transgenic mice. The loss of LacZ
expression may result from the ongoing pathological pro-
cess occurring in YAC72 mice and suggests that this
reporter gene could be used as a surrogate marker to follow
the appearance of HD pathology in animal models lacking
severe neurodegeneration. Whether this loss of LacZ stain-
ing is due to an aberrant transcriptional regulation of the
reporter gene, as reported in various experimental paradigms
of HD, still needs to be investigated. The cell bodies of
some spared LacZ-positive neurons appear larger with an
intense staining. This phenotype is reminiscent of the results
published by Bence et al. (2001). They showed that cells co-
expressing a mutated huntingtin fragment and a destabilized
green fluorescent protein (GFP) have a 4-fold increase in
GFP fluorescence compared to controls and that this phe-
nomenon was due to an impairment of the ubiquitin–
proteasome pathway. Interestingly, no significant differen-
ces in CNTF expression were observed over time or
between wild-type and YAC72 mice. This suggests that
CNTF expression, contrary to LacZ, is not affected by
mutated huntingtin or that CNTF is altering the ongoing
pathology.
During the time-course examined in our experiments,
the phenotype of YAC72 transgenic mice appears to
correspond to early stages of the disease, with hyperactiv-
ity and neuronal dysfunction associated with the appear-
ance of dark cells. While nuclear huntingtin staining
increases around 12 months of age, very few huntingtin
inclusions are identified. This experimental paradigm was
used to assess the impact of a local and continuous
expression of approximately 0.5 ng human CNTF in the
striatum. Wild-type FVB/N littermates were used as con-
trol. The development of hyperactivity on open-field test-
ing was the first parameter examined to assess the disease
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inter- and intra-individual variability of spontaneous ex-
plorative behavior was observed, but significant differences
were recorded between wild-type and transgenic mice at 5
and 8 months. This heterogeneity and the early stage of the
pathology in YAC72 mice characterized by subtle changes,
limits the number of validated outcome measures which
can reliably be used to monitor the effects of potential
therapeutic candidates. Nuclear inclusions are, for example,
very rare in these animals and cannot be used as parameter.
Recently, a new YAC128 transgenic mouse model of HD
has been developed which has increased levels of trans-
gene expression and an accelerated neurodegenerative
phenotype that is more adequate for therapeutic trials
(Slow et al., 2003).
Scattered atrophic neurons with condensed chromatin
and a ‘‘dark’’ cytoplasm are present in affected areas of
HD brains (Vonsattel and Difiglia, 1998). In 17-week-old
R6/2 transgenic mice, degenerating neurons surrounded by
neurons with normal appearance were detected in cerebel-
lum and large number of brain regions. These dying neurons
have a higher affinity for toluidine blue and exhibit nuclear
inclusions and ruffling of the plasma membrane (Turmaine
et al., 2000). Dark neurons were also observed in 5- to 7-
month-old R6/1 mice (Iannicola et al., 2000) and in 8- to 12-
month-old YAC72 mice (Hodgson et al., 1999). In our
study, hyperchromatic and shrunken neurons were visible
in YAC72-LacZ mice, and CNTF expression significantly
decreases the number of dark neurons. Whether these dark
cells represent a degenerating subpopulation of neurons is,
however, unclear.
Mutant huntingtin expression is associated with regional
and temporal alterations in gene expression (Neri, 2001;
Nucifora et al., 2001; Shimohata et al., 2000; Sugars and
Rubinsztein, 2003). Changes in the expression of transcrip-
tion factors, neuronal markers, genes implicated in cellular
metabolism or neurotransmitter receptors should, not
only, provide important information related to polyQ-me-
diated neurodegeneration but also quantitative tools for
the evaluation of therapeutic strategies. Histological
studies on R6/2 animals has, for example, revealed a
reduction in DARPP-32 and other dopamine-regulated
proteins expressed in medium spiny neurons at 4–8 weeks
(Bibb et al., 2000; van Dellen et al., 2000). DARPP-32 is a
pivotal regulator of dopamine receptor signaling in the
striatum and is therefore considered as a good marker of
the pathology occurring in presymptomatic mice or early
stage of the disease. Interestingly, CNTF expression in-
duced a drastic down-regulation of DARPP-32 in wild-type
mice 9 months post-lentiviral injection. This effect has not
been observed when the same CNTF-expressing lentiviral
vector was injected for 5–12 weeks in QA-lesioned rats (de
Almeida et al., 2001; unpublished data) or when CNTF was
delivered in 3-NP-lesioned primates by encapsulated genet-
ically engineered BHK cells (Mittoux et al., 2000). How the
long-term striatal expression of CNTF leads to a decrease inDARPP-32 immunoreactivity, and how this change might
affect striatal function still needs to be established. The
continuous delivery of nanograms of CNTF was previously
shown to drastically decrease the extent of striatal damage
in drug-induced models of HD (de Almeida et al., 2001;
Emerich et al., 1996, 1997a,b; Mittoux et al., 2000).
Differences in the pathological processes between drug-
induced and genetic models of HD may lead to a differen-
tial effect of CNTF. The mode of action of this cytokine is
still poorly understood and various intracellular pathways
might be activated in various animal models of HD. The
binding of the CNTF to the gp130/LIFRh/CNTFRa recep-
tor complex has been shown to activate the Jack/STAT and
PI3K/Akt signaling pathways (Alonzi et al., 2001). CNTF,
in particular, induces the phosphorylation and nuclear
translocation of Stat3, a protein inducing the transcription
of Bcl-2 and Bcl-xL genes (Catlett-Falcone et al., 1999;
Fukuda et al., 1998; Karni et al., 1999) and regulating the
activity of several transcription factors such as Forkhead 1,
CREB and NF-kB (Brunet et al., 1999; Du and Montminy,
1998; Kane et al., 1999; Ozes et al., 1999). Long-term
expression of CNTF may affect striatal functions either
directly or indirectly. It is well established that CNTF
induces a phenotypic alteration of astrocytes in vivo
(Gomes et al., 1999; Kahn et al., 1997a,b; Levison et al.,
1998; Lisovoski et al., 1997; Winter et al., 1995). Consis-
tent with this, we observed an up-regulation of the astro-
cytic marker GFAP in the striatum of Lenti-CNTF injected
mice. This astrocytic response covers the entire striatum
and is probably due to diffusion of CNTF throughout this
structure. Recently, Albrecht et al. (2002) showed that
CNTF treatment leads to an activation of spinal cord
astrocytes, to the production of various growth factors
and to an increased survival of CNS neurons compared to
untreated astrocytes. They propose that cytokine-activated
astrocytes have an enhanced buffering capacity leading to
decreased levels of harmful energy metabolites, which may
indirectly protect neurons. This same indirect CNTF-medi-
ated mechanism could be activated in the striatum and
therefore protect neurons undergoing degeneration. Chronic
impairment of mitochondrial energy metabolism are indeed
thought to be involved in neurodegenerative diseases,
including HD.
Studies are needed to further assess CNTF effect on
striatal functions and its impact on HD pathology
corresponding not only to an early stage of the disease but
also to grade 2–4 pathologies.Acknowledgments
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